Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders

Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli Lilly, maker of the amyloid-targeting Alzheimer’s drug Kisunla, participated in the startup’s new financing.

The post Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders appeared first on MedCity News.

Leave a Reply

Your email address will not be published. Required fields are marked *